(MENAFN Press) Aarkstore.com announces, a new market research report is available in its vast collection:
Metastatic Brain Tumor “ Pipeline Review, H1 2012
Search for this keyword : Pipeline Review, H1 2012
http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H1 2012&PubId=&pagenum=1
Global Markets Direct's, Metastatic Brain Tumor - Pipeline Review, H1 2012, provides an overview of the Metastatic Brain Tumor therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Brain Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Brain Tumor. Metastatic Brain Tumor - Pipeline Review, H1 2012 is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Metastatic Brain Tumor.
- A review of the Metastatic Brain Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Metastatic Brain Tumor pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Metastatic Brain Tumor.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Metastatic Brain Tumor pipeline depth and focus of Metastatic Brain Tumor therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents :
List of Tables 4
List of Figures 4
Global Markets Direct Report Coverage 5
Metastatic Brain Tumor Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Metastatic Brain Tumor 7
Metastatic Brain Tumor Therapeutics under Development by Companies 9
Metastatic Brain Tumor Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Metastatic Brain Tumor Therapeutics “ Products under Development by Companies 14
Metastatic Brain Tumor Therapeutics “ Products under Investigation by Universities/Institutes 15
Companies Involved in Metastatic Brain Tumor Therapeutics Development 16
Celtic Pharmaceutical Holdings L.P. 16
Metastatic Brain Tumor “ Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
Xerecept - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Dendritic Cell Vaccine - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Temozolomide Etoposide Trofosfamid - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Sorafenib Temozolomide Radiation Therapy - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Temozolomide Temsirolimus - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Sorafenib Radiation Therapy - Drug Profile 30
Product Description 30
Mechanism of Action 30
More Related Reports :
Liver Cirrhosis “ Pipeline Review, H1 2012
Systemic Sclerosis (Scleroderma) “ Pipeline Review, H1 2012
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) “ Pipeline Review, H1 2012
Septic Shock “ Pipeline Review, H1 2012
Iron Deficiency Anemia “ Pipeline Review, H1 2012
Vaginal Cancer “ Pipeline Review, H1 2012
AIDS - Related Cancer “ Pipeline Review, H1 2012
Vulvar Cancer “ Pipeline Review, H1 2012
Throat Cancer “ Pipeline Review, H1 2012
Adrenocortical Carcinoma (Adrenal Cortex Cancer) “ Pipeline Review, H1 2012
Astrocytoma “ Pipeline Review, H1 2012
Plasma Cell Neoplasm “ Pipeline Review, H1 2012
Hypopharyngeal Cancer “ Pipeline Review, H1 2012
Squamous Cell Carcinoma “ Pipeline Review, H1 2012
Osteosarcoma “ Pipeline Review, H1 2012
Pediatric Cancer “ Pipeline Review, H1 2012
For More details about above & other Reports plz contact :
Contact: Marketing team
You can also request for sample page of above mention reports on email@example.com